Purpose of the Procedure
- Determining the effectiveness of immunotherapy.
- Quantifying PD-L1 protein on tumor cells.
- Avoiding treatments the tumor may not respond to.
Book PD-L1 Expression Test in KSA | Lahalak Medical Platform
This essential biomarker test determines tumor response to modern immunotherapy. By quantifying PD-L1 expression, oncologists can design precise, personalized treatment plans tailored to individual patient needs for optimal clinical outcomes.
Scientific name: PD-L1 Protein Expression Immunohistochemistry Test
An immunohistochemistry assay quantifying PD-L1 protein expression on tumor cells. It predicts response to immune checkpoint inhibitors, helping oncologists select the most effective immunotherapy for various cancer types.
Service type
Laboratory Pathology Test
Duration
7-10 working days
Fasting
Fasting is not required
Included Services
- Immunohistochemistry analysis
- Detailed expression percentage report
- Pathologist review of results
Medical Service Information
When is this test ordered?
- Diagnosis of non-small cell lung cancer (NSCLC).
- Advanced bladder or kidney cancer cases.
- Evaluating treatment options for melanoma patients.
Understanding the Results
- Positive results indicate a higher likelihood of responding to immunotherapy.
- Negative results may suggest alternative treatments like chemotherapy.
- Results are often reported as a percentage (Tumor Proportion Score).
Conditions & Notices
- Requires a tissue sample (paraffin block) from the tumor
- Previous pathology report must be provided
Medical services you might also like
